HomeInsightsStock Comparison

Aarti Drugs Ltd vs Aarti Pharmalabs Ltd Stock Comparison

Aarti Drugs Ltd vs Aarti Pharmalabs Ltd Stock Comparison

Last Updated on: Jun 07, 2025

Key Highlights

  • The Latest Trading Price of Aarti Drugs Ltd is ₹ 462.05 as of 06 Jun 15:30.
  • The P/E Ratio of Aarti Drugs Ltd changed from 8.3 on March 2020 to 23.3 on March 2024 . This represents a CAGR of 22.93% over 5 yearsThe P/E Ratio of Aarti Pharmalabs Ltd changed from 12.9 on March 2023 to 18.2 on March 2024 . This represents a CAGR of 18.78% over 2 years.
  • The Market Cap of Aarti Drugs Ltd changed from ₹ 1178 crore on March 2020 to ₹ 3988 crore on March 2024 . This represents a CAGR of 27.61% over 5 yearsThe Market Cap of Aarti Pharmalabs Ltd changed from ₹ 2489 crore on March 2023 to ₹ 3942 crore on March 2024 . This represents a CAGR of 25.85% over 2 years.
  • The revenue of Aarti Drugs Ltd for the Mar '25 is ₹ 678.63 crore as compare to the Dec '24 revenue of ₹ 568.5 crore. This represent the growth of 19.37% The revenue of Aarti Pharmalabs Ltd for the Mar '25 is ₹ 562.17 crore as compare to the Dec '24 revenue of ₹ 542.81 crore. This represent the growth of 3.57%.
  • The ebitda of Aarti Drugs Ltd for the Mar '25 is ₹ 95.2 crore as compare to the Dec '24 ebitda of ₹ 73.62 crore. This represent the growth of 29.31% The ebitda of Aarti Pharmalabs Ltd for the Mar '25 is ₹ 144.02 crore as compare to the Dec '24 ebitda of ₹ 133.64 crore. This represent the growth of 7.77%.
  • The net profit of Aarti Drugs Ltd changed from ₹ 47.97 crore to ₹ 62.77 crore over 8 quarters. This represents a CAGR of 14.39% The net profit of Aarti Pharmalabs Ltd changed from ₹ 47.09 crore to ₹ 88.34 crore over 8 quarters. This represents a CAGR of 36.97% .
  • The Dividend Payout of Aarti Drugs Ltd changed from 3.43 % on March 2020 to 6.48 % on March 2024 . This represents a CAGR of 13.57% over 5 yearsThe Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 13.55 % on March 2024 . This represents a CAGR of 13.33% over 2 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aarti Drugs Ltd

  • Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
  • The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
  • With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
  • It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
  • It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

About Aarti Pharmalabs Ltd

  • Aarti Pharmachem Limited was incorporated as a Public Limited Company in 2019.
  • The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine Derivatives situated in India. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.
  • It expanded block for CSD, Vapi and API, Tarapur units in 2022. The Scheme of Arrangement for the demerger of Pharma Business Undertaking from Aarti Industries Limited into its wholly owned subsidiary Aarti Pharmalabs Limited was effective on October 17, 2022 and operational from July 1, 2021.

Aarti Drugs Ltd News Hub

News

Aarti Drugs to convene board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 6 May 2025. Po...

Read more

30 Apr 2025 11:38

News

Aarti Drugs receives affirmation in credit ratings from ICRA

Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for ...

Read more

31 Jan 2025 19:10

News

Aarti Drugs gains as PAT rises to Rs 37 cr in Q3; declares dividend of Re 1/sh

Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as comp...

Read more

30 Jan 2025 12:14

News

Board of Aarti Drugs recommends Interim Dividend

Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 29...

Read more

29 Jan 2025 17:03

News

Aarti Drugs to conduct board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 29 January 202...

Read more

23 Jan 2025 11:25

News

Aarti Drugs's receives Establishment Inspection Report for API manufacturing unit

Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the i...

Read more

24 Dec 2024 15:12

Aarti Pharmalabs Ltd News Hub

News

Board of Aarti Pharmalabs recommends final dividend

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held ...

Read more

12 May 2025 09:19

News

Aarti Pharmalabs Q4 PAT climbs 35% YoY to Rs 88 cr

Revenue from operations jumped 11.46% YoY to Rs 563.78 crore in the quarter ended 31 March...

Read more

12 May 2025 10:44

News

Aarti Pharmalabs to conduct board meeting

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 10 May 20...

Read more

25 Apr 2025 11:27

News

Aarti Pharmalabs achieves SBTi approval for its emission reduction goals

Aarti Pharmalabs announced that its ambitious Science Based Targets (SBTs) for emissions h...

Read more

16 Apr 2025 16:40

News

Aarti Pharmalabs spurts after Q3 PAT climbs 40% YoY to Rs 74 cr

Revenue from operations grew 19.9% to Rs 537.78 crore in the quarter ended 31 December 202...

Read more

06 Feb 2025 11:08

News

Board of Aarti Pharmalabs recommends interim dividend

Aarti Pharmalabs announced that the Board of Directors of the Company at its meeting held ...

Read more

05 Feb 2025 20:52

SWOT Analysis Of Aarti Pharmalabs Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Aarti Drugs Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Aarti Pharmalabs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aarti Drugs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aarti Drugs Ltd and Aarti Pharmalabs Ltd

Which company has a larger market capitalization, Aarti Drugs Ltd or Aarti Pharmalabs Ltd?

Market cap of Aarti Drugs Ltd is 4,247 Cr while Market cap of Aarti Pharmalabs Ltd is 8,246 Cr

What are the key factors driving the stock performance of Aarti Drugs Ltd and Aarti Pharmalabs Ltd?

The stock performance of Aarti Drugs Ltd and Aarti Pharmalabs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Drugs Ltd and Aarti Pharmalabs Ltd?

As of June 7, 2025, the Aarti Drugs Ltd stock price is INR ₹462.05. On the other hand, Aarti Pharmalabs Ltd stock price is INR ₹909.85.

How do dividend payouts of Aarti Drugs Ltd and Aarti Pharmalabs Ltd compare?

To compare the dividend payouts of Aarti Drugs Ltd and Aarti Pharmalabs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions